Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 7/20 | 0.39 |
| ▸ | CA2 | P00918 | 7/20 | 0.39 |
| ▸ | CA9 | Q16790 | 7/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14347806 | 0.79 | TSHR (0.50) | MAPTALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL3049226 | 0.77 | CA2 (0.45) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL12161965 | 0.76 | NR3C2 (0.47) | MAPTALDH1A1CYP3A4KMT2ACYP2C19 | |
| SCHEMBL24750662 | 0.75 | ALDH1A1 (0.43) | MAPTALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL17560554 | 0.75 | TSHR (0.48) | ALDH1A1CYP3A4MAPK1TSHRLMNA | |
| Sulfuric Acid SCHEMBL8639733 | 0.73 | TSHR (0.48) | MAPTALDH1A1CYP3A4MEN1KMT2A | |
| Sulfuric Acid SCHEMBL28754418 | 0.73 | ALDH1A1 (0.58) | MAPTALDH1A1CYP3A4MEN1KMT2A | |
| Sulfuric Acid SCHEMBL28754417 | 0.73 | ALDH1A1 (0.58) | MAPTALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL10700977 | 0.71 | LMNA (0.42) | ALDH1A1CYP3A4CYP1A2CYP2C19TSHR | |
| SCHEMBL2046051 | 0.71 | CA1 (0.51) | ALDH1A1MAPK1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| CN-117396480-A | Pyrazolopyrimidinone compounds | 奥弗恩制药公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022204481-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-2329821-B1 | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema | GLAXOSMITHKLINE LLC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2329821-A1 | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema | GlaxoSmithKline LLC (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-2329821-A1 | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema | GlaxoSmithKline LLC (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-1968594-B1 | TREATMENT OF OCULAR NEOVASCULAR DISORDERS SUCH AS MACULAR DEGENERATION, ANGIOD STREAKS, UVEITIS AND MACULAR EDEMA | GLAXOSMITHKLINE LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20070208023-A1 | Cancer Treatment Method | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208023-A1 | Cancer Treatment Method | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2007064752-A2 | TREATMENT OF OCULAR NEOVASCULAR DISORDERS SUCH AS MACULAR DEGENERATION, ANGIOD STREAKS, UVEITIS AND MACULAR EDEMA | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064752-A2 | TREATMENT OF OCULAR NEOVASCULAR DISORDERS SUCH AS MACULAR DEGENERATION, ANGIOD STREAKS, UVEITIS AND MACULAR EDEMA | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1755394-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060252943-A1 | Chemical process | SMITHKLINE BEECHAM CORPORATION | 2006-11-09 | — | — | US | disclosed |
| EP-1515955-A4 | CHEMICAL PROCESS | SMITHKLINE BEECHAM CORP (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005105094-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-10 | — | — | WO | disclosed |
| EP-1515955-A2 | CHEMICAL PROCESS | SmithKline Beecham Corporation (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003106416-A2 | CHEMICAL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208023-A1 | Cancer Treatment Method | TP53, TYMP, TOP2A | MAPT 3329/4885ALDH1A1 965/4885CYP3A4 132/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | MAPT 3283/4885ALDH1A1 3576/4885CYP3A4 2048/4885 |
| US-20060252943-A1 | Chemical process | KDR, FLT4, FLT1 | MAPT 3266/4885ALDH1A1 980/4885CYP3A4 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.